"Americans will put up with anything provided it doesn't block traffic.” ? Dan Rather
Today, we look at a small 'Tier 4' biopharma concern that has had a volatile ride in its five years as a public company.
Company Overview:
Matinas BioPharma (MTNB) IPO’d in 2014 and is a Bedminster, New Jersey-based clinical-stage biopharmaceutical company. The company is advancing drug candidates born from their LNC drug delivery platform, which is intended to overcome a variety of limitations that accompany modern drug delivery vehicles. Matinas BioPharma has a market capitalization of